Safety and Activity of F14 for Management of Pain Following Total Knee Replacement
Status:
Completed
Trial end date:
2020-03-30
Target enrollment:
Participant gender:
Summary
The safety and activity of a single, 3.5 mL dose of F14 (celecoxib) concurrent with standard
of care analgesia administered following total knee replacement will be compared to standard
of care analgesia alone.